All In Biotech

Drug Trial Radar · NCT04767802

PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit

A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit (PACIFIC)

Last checked: Nov 20, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Feb 2, 2021

Primary completion

Mar 15, 2023

Study completion Mar 15, 2023

Sponsor

Lead sponsor
Protagonist Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, single arm trial of PTG-300 in subjects with PV who are newly diagnosed or for whom current therapy is not sufficient to control their hematocrit and have hematocrit \>48% prior to dosing. The PTG-300 dose and schedule may be adjusted every 2 to 4 weeks to maintain hematocrit \<45% with a target of \<43%. Subjects may receive PTG-300 treatment for up to 52 weeks.

Conditions

  • Polycythemia Vera

Interventions

  • PTG-300Drug

    Hepcidin mimetic

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate PTG-300's efficacy in subjects with PV and baseline elevated hematocrit.Time frame: Estimate the proportion of subject with a hematocrit less than 45% at Week 16

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Hospital Sultanah Aminah

    Johor Bahru, Johor, Malaysia

  • Hospital Raja Perempuan Zainab

    Kota Bharu, Kelantan, Malaysia

  • Hospital Raja Permaisuki Bainun

    Ipoh, Perak, Malaysia

  • Hospital Umum Sarawak

    Kuching, Sarawak, Malaysia

  • Hospital Ampang

    Ampang, Selangor, Malaysia

  • Gachon University Medical Center

    Incheon, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Seoul St. Mary's Catholic University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.